Publications
Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.
Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial
Nat Med. 2023; online ahead of print DOI: 10.1038/s41591-023-02597-w
The use of antiobesity medications following intensive lifestyle intervention has been proposed as a strategy to induce additional weight reduction (which may be needed to achieve optimal control of obesity-related complications) or, at a minimum, to prevent weight regain. The effects of tirzepatide, the dual GIP and GLP-1RA, on weight reduction after successful intensive lifestyle intervention are unknown.
Keywords:
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
N Engl J Med. 2023; DOI: 10.1056/NEJMoa2302392
Orforglipron is a once-daily oral nonpeptide GLP-1RA in development for weight management and the treatment of T2D. This phase 2 double-blind trial evaluated the efficacy and safety of orforglipron in adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without T2D. In total, 272 participants were randomised to orforglipron (12, 24, 36 or 45 mg) or placebo once daily for 36 weeks, with a primary endpoint of change from baseline in body weight at week 26.
Keywords:
The Impact of Obesity on Cardiovascular and Kidney Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Treated with Finerenone: Post hoc analysis of the FIDELITY Study
Diabetes Obes Metab. 2023 doi Epub ahead of print : 10.1111/dom.15197
Patients with obesity may benefit more from treatment with mineralocorticoid receptor antagonists given their higher levels of circulating aldosterone and therefore potentially higher levels of MRs in visceral fat. The aim of this analysis was to assess the effect of finerenone on the risk of cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes, with and without obesity.
Keywords:
Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet. 2023. DOI: 10.1016/S0140-6736(23)01185-6
Oral semaglutide 7 mg and 14 mg once-daily are approved for the treatment of T2D and improve glycaemic control with accompanying body weight reductions. A higher dose of once-daily oral semaglutide 50 mg is currently being investigated for the treatment of obesity in people with overweight or obesity, and for glycaemic control in people with T2D. The OASIS 1 trial assessed once-daily oral semaglutide 50 mg in adults with overweight or obesity, without T2D.
Keywords:
Efficacy and Safety of Tirzepatide for Treatment of Overweight or Obesity. A Systematic Review and Meta-analysis
Int J Obes (Lond). 2023. DOI: 10.1038/s41366-023-01321-5
This systematic review and meta-analysis aimed to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity.
Keywords:
The Improved Health Utility of Once-Weekly Subcutaneous Semaglutide 2.4 mg Compared With Placebo in the STEP 1-4 Obesity Trials
Diabetes Obes Metab 2023 DOI 10.1111/dom.15090
Patient-reported outcomes and evaluations serve to shape policy through cost-effectiveness comparisons, assessing the incremental expenses of an intervention against the incremental enhancement in quality-adjusted life years.
Keywords:
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
Diabetes Care. 2023; online ahead of print DOI: 10.2337/dc22-1889
In the STEP trials, semaglutide markedly reduced body weight and improved glycaemic control in adults with overweight or obesity with/without T2D. However, the effects of semaglutide on albuminuria and eGFR are unknown.
Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 trial
Eur Heart J 2022;43:2958-67 doi.org/10.1093/eurheartj/ehab530
In the DECLARE-TIMI 58 trial, patients with type 2 diabetes and higher body weight were more likely to have hospitalisation for heart failure (HHF) and atrial fibrillation or flutter (AF/AFL).
Semaglutide in Type 2 Diabetes With Chronic Kidney Disease at High Risk of Progression: Real-World Clinical Practice
Clin Kidney J 2022;15(8);1593-600 doi: 10.1093/ckj/sfac096
In this real-world study, patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) treated with semaglutide significantly improved glycaemic control and decreased weight.
Effect of Semaglutide and Liraglutide in Individuals With Obesity or Overweight Without Diabetes: A Systematic Review
Ther Adv Chronic Dis 2022;13:1-14 doi: 10.1177/20406223221108064
This systematic literature review found liraglutide and semaglutide led to clinically relevant (≥5%) weight loss in 48.2–88.7% of obese or overweight adults without diabetes.
Data on the effects of liraglutide and semaglutide in diabetes are well-known, but therapeutic outcomes in obese or overweight individuals without diabetes have not been summarised. This systematic review aimed to evaluate their effects in this population, and 18 studies representing 10,938 patients were included.